--- title: Evidence | Peer-reviewed ctDNA performance data description: "Explore the published evidence behind SiMSen-Seq: peer-reviewed studies, performance data and real-world results in circulating tumour DNA detection." --- [Skip to the main content.](https://simsendiagnostics.com/evidence-hub#main-content) [![Simsen logotype](https://simsendiagnostics.com/hs-fs/hubfs/SD_logo%20medium-2.png?width=588&height=164&name=SD_logo%20medium-2.png "Simsen logotype")](https://simsendiagnostics.com?hsLang=en) [![Simsen logotype](https://simsendiagnostics.com/hs-fs/hubfs/SD_logo%20medium-2.png?width=588&height=164&name=SD_logo%20medium-2.png "Simsen logotype")](https://simsendiagnostics.com?hsLang=en) - [PLATFORM](https://simsendiagnostics.com/platform) - [Why Simsen](https://simsendiagnostics.com/why-simsen) - [Our technology](https://simsendiagnostics.com/platform-our-technology) - [Methodology](https://simsendiagnostics.com/platform-methodology) - [Find your approach](https://simsendiagnostics.com/find-your-approach) - [Delivered your way](https://simsendiagnostics.com/both-delivery-models) - [Solutions](https://simsendiagnostics.com/solutions-overview) - [EVIDENCE](https://simsendiagnostics.com/evidence-hub) - [Publications](https://simsendiagnostics.com/evidence-publications) - [Paediatric solid tumours](https://simsendiagnostics.com/evidence-paediatric-solid-tumours) - [CNS tumours & CSF ctDNA](https://simsendiagnostics.com/evidence-cns-csf-ctdna) - [White papers](https://simsendiagnostics.com/evidence-white-paper-ctdna-trials) - [COMPANY](https://simsendiagnostics.com/company-about) - [About us](https://simsendiagnostics.com/company-about) - [Team](https://simsendiagnostics.com/company-team) - [Contact us](https://simsendiagnostics.com/company-contact) - [News](https://simsendiagnostics.com/news) - [RESOURCES](https://simsendiagnostics.com/resources-hub) - [Sample collection guides](https://simsendiagnostics.com/resources-sample-collection-guides) - [Baseline kit guide](https://simsendiagnostics.com/baseline-collection-kit) - [Follow-up kit guide](https://simsendiagnostics.com/resources-followup-collection-kit) Search [![Request a conversation](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/25734893/interactive-412216133822.png)](https://simsendiagnostics.com/hs/cta/wi/redirect?encryptedPayload=AVxigLJhdPpF%2BC9YCwotj1YkLcE%2B0%2FdwxEzIaz%2FsH3UIBQq1mnsH%2Bp%2BDkEJzdHXn243Wom0974Go8vBa%2BclZakOwJPa78TMqbUqXRxouJ6WBiirkkpuWxvXssDmfZ7kWSdwFavbxzvtQYNA4Gd%2Fjnc%2B6ThhRc6thkUx9FRQe91E7nFWpzmPTwmvuT6iA753Ml3zBKxylhTmT&webInteractiveContentId=412216133822&portalId=25734893&hsLang=en) Toggle Menu Search Toggle Menu [![Request a conversation](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/25734893/interactive-412216133822.png)](https://simsendiagnostics.com/hs/cta/wi/redirect?encryptedPayload=AVxigLJhdPpF%2BC9YCwotj1YkLcE%2B0%2FdwxEzIaz%2FsH3UIBQq1mnsH%2Bp%2BDkEJzdHXn243Wom0974Go8vBa%2BclZakOwJPa78TMqbUqXRxouJ6WBiirkkpuWxvXssDmfZ7kWSdwFavbxzvtQYNA4Gd%2Fjnc%2B6ThhRc6thkUx9FRQe91E7nFWpzmPTwmvuT6iA753Ml3zBKxylhTmT&webInteractiveContentId=412216133822&portalId=25734893&hsLang=en) - [PLATFORM](https://simsendiagnostics.com/platform) - [Why Simsen](https://simsendiagnostics.com/why-simsen) - [Our technology](https://simsendiagnostics.com/platform-our-technology) - [Methodology](https://simsendiagnostics.com/platform-methodology) - [Find your approach](https://simsendiagnostics.com/find-your-approach) - [Delivered your way](https://simsendiagnostics.com/both-delivery-models) - [Solutions](https://simsendiagnostics.com/solutions-overview) - [EVIDENCE](https://simsendiagnostics.com/evidence-hub) - [Publications](https://simsendiagnostics.com/evidence-publications) - [Paediatric solid tumours](https://simsendiagnostics.com/evidence-paediatric-solid-tumours) - [CNS tumours & CSF ctDNA](https://simsendiagnostics.com/evidence-cns-csf-ctdna) - [White papers](https://simsendiagnostics.com/evidence-white-paper-ctdna-trials) - [COMPANY](https://simsendiagnostics.com/company-about) - [About us](https://simsendiagnostics.com/company-about) - [Team](https://simsendiagnostics.com/company-team) - [Contact us](https://simsendiagnostics.com/company-contact) - [News](https://simsendiagnostics.com/news) - [RESOURCES](https://simsendiagnostics.com/resources-hub) - [Sample collection guides](https://simsendiagnostics.com/resources-sample-collection-guides) - [Baseline kit guide](https://simsendiagnostics.com/baseline-collection-kit) - [Follow-up kit guide](https://simsendiagnostics.com/resources-followup-collection-kit) [For clinical trials Pharma and CROs Validate MRD endpoints, cut trial-arm cost, build EU regulatory readiness. Design a trial assay →](https://simsendiagnostics.com/solutions-trials?hsLang=en) [For research and labs Translational oncology See signal in paediatric and early-stage samples your current platform misses. Send samples or run SiMSen-Seq in-house. See the signal →](https://simsendiagnostics.com/solutions-research?hsLang=en) [For clinics Premium oncology monitoring Detect minimal residual disease ahead of imaging. Logistics across the EU, UK and EEA. Detect relapse earlier →](https://simsendiagnostics.com/solutions-clinic?hsLang=en) [Home](https://simsendiagnostics.com?hsLang=en) / Evidence Evidence # See what you could detect *before* you commit a sample. The published science, the disease-area reviews and the practical guides, each framed around what the data means for your trial, your laboratory and your patients. Start with what matters to your work, then go straight to the source. what ultra-sensitivity delivers ## Performance in numbers, from the work already done. 0.001 % VAF Variant allele frequency you can detect, in your own samples. [Poster →](https://simsendiagnostics.com/hubfs/Posters/poster_ctdna_symposium_aarhus_2026.pdf?hsLang=en) 9 months Earlier than imaging picked up relapse, in paediatric neuroblastoma monitoring. [Ek et al., 2024 →](https://doi.org/10.1158/2767-9764.CRC-24-0338) 68 % Of surveillance scans could have been avoided, in ctDNA-monitored metastatic breast cancer. [MOUHANNA ET AL., 2025 →](https://doi.org/10.1002/ijc.35292) ![Publications icon](https://simsendiagnostics.com/hubfs/book.svg) ### Publications Peer-reviewed papers, each with a plain-language note on what the result means for you and a permanent link to the source. [Browse publications →](https://simsendiagnostics.com/evidence-publications?hsLang=en) ![globe](https://simsendiagnostics.com/hubfs/globe.svg) ### Disease areas Deep reviews by indication: paediatric solid tumours, and CNS tumours read in cerebrospinal fluid. The evidence, the data, and what each lets you do. [Explore paediatric solid tumours →](https://simsendiagnostics.com/evidence-paediatric-solid-tumours?hsLang=en) [Explore CNS tumours reads through CSF →](https://simsendiagnostics.com/evidence-cns-csf-ctdna?hsLang=en) ![download](https://simsendiagnostics.com/hubfs/download.svg) ### White papers Practical guides from our scientific team, starting with how to design a ctDNA endpoint into an oncology trial. [Open the form →](https://simsendiagnostics.com/evidence-white-paper-ctdna-trials?hsLang=en) Latest evidence ## Start with these three. A review, a guide and a result. The full, filterable list lives on the **[Publications](https://simsendiagnostics.com/evidence-publications?hsLang=en)** page. Disease area ### CNS tumours: reading glioma in the cerebrospinal fluid. What CSF ctDNA lets neuro-oncology teams do that plasma cannot, with the sensitivity data and the Epistamai Bio case behind it. [Read the review →](https://simsendiagnostics.com/evidence-cns-csf-ctdna?hsLang=en) Disease area ### Paediatric solid tumours: detecting relapse before imaging can. What ultra-sensitive ctDNA lets paediatric teams do that they currently cannot, with the sensitivity data and evidence behind it. [Read the review →](https://simsendiagnostics.com/evidence-paediatric-solid-tumours?hsLang=en) White paper ### Circulating tumour DNA as a biomarker in clinical trials. For pharma and CRO teams: MRD enrichment, response monitoring and ctDNA endpoints, and how they cut trial size and cost. [Get the white paper →](https://simsendiagnostics.com/evidence-white-paper-ctdna-trials?hsLang=en) Using the evidence ### Can't find evidence for your indication? Tell our scientific team what you are working on and we will point you to the most relevant data, including unpublished work we can share under agreement. [Contact the scientific team →](https://simsendiagnostics.com/company-contact?hsLang=en) How is this different from the Publications page? This hub brings the different kinds of evidence together: papers, disease-area reviews and white papers. Publications is the deeper, fully citable list of peer-reviewed work on its own. Why do papers link to the publisher rather than a PDF? Peer-reviewed papers are copyright of the publisher, so we link to the version of record via its DOI, which is permanent and authoritative. Where a paper is open access, we may also offer the PDF. Which materials can I download straight away? Our own white papers are hosted here. Some ask for a few details first so we can stay in touch. Talk to us ### Speak to our scientific team. A real human, in CET/CEST time zone, who has run samples like yours. [inbox@simsendiagnostics.com →](mailto:inbox@simsendiagnostics.com)   ![full_lockup_white_CMYK kopia](https://simsendiagnostics.com/hs-fs/hubfs/full_lockup_white_CMYK%20kopia.png?width=166&height=45&name=full_lockup_white_CMYK%20kopia.png) **Visiting and postal address:** Pepparedsleden 1 431 53 Mölndal, Sweden **Shipping address:** c/o AstraZeneca R&D Mölndal Pepparedsleden 3 431 53 Mölndal, Sweden PLATFORM PLATFORM - [Platform overview](https://simsendiagnostics.com/platform) - [Why Simsen](https://simsendiagnostics.com/why-simsen) - [Our technology](https://simsendiagnostics.com/platform-our-technology) - [Delivered your way](https://simsendiagnostics.com/both-delivery-models) SOLUTIONS SOLUTIONS - [For clinical trials](https://simsendiagnostics.com/solutions-trials) - [For research and labs](https://simsendiagnostics.com/solutions-research) - [For clinics](https://simsendiagnostics.com/solutions-clinic) - [Solutions overview](https://simsendiagnostics.com/solutions-overview) COMPANY COMPANY - [About](https://simsendiagnostics.com/company-about) - [News](https://simsendiagnostics.com/news) - [Team](https://simsendiagnostics.com/company-team) - [Contact](https://simsendiagnostics.com/company-contact) - [Privacy policy](https://simsendiagnostics.com/legal-privacy-policy) - [Cookie Policy](https://simsendiagnostics.com/legal-cookie-policy) - [Terms of use](https://simsendiagnostics.com/legal-terms-of-use) © 2026 Simsen Diagnostics AB, All rights reserved. [Linkedin](https://www.linkedin.com/company/simsendiagnostics) Return to top